Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/23147
Full metadata record
DC FieldValueLanguage
dc.contributor.authorOpstelten, Rianne-
dc.contributor.authorde Kivit, Sander-
dc.contributor.authorSlot, Manon C-
dc.contributor.authorvan den Biggelaar, Maartje-
dc.contributor.authorIwaszkiewicz-Grześ, Dorota-
dc.contributor.authorGliwiński, Mateusz-
dc.contributor.authorScott, Andrew M-
dc.contributor.authorBlom, Bianca-
dc.contributor.authorTrzonkowski, Piotr-
dc.contributor.authorBorst, Jannie-
dc.contributor.authorCuadrado, Eloy-
dc.contributor.authorAmsen, Derk-
dc.date2020-05-04-
dc.date.accessioned2020-05-12T07:04:56Z-
dc.date.available2020-05-12T07:04:56Z-
dc.date.issued2020-05-04-
dc.identifier.citationJournal of immunology (Baltimore, Md. : 1950) 2020; online first: 4 May-
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/23147-
dc.description.abstractFOXP3-expressing regulatory T (Treg) cells safeguard immunological tolerance. Treg cells can be generated during thymic development (called thymic Treg [tTreg] cells) or derived from mature conventional CD4+ T cells that underwent TGF-β-mediated conversion in the periphery (called peripheral Treg [pTreg] cells). Murine studies have shown that tTreg cells exhibit strong lineage fidelity, whereas pTreg cells can revert into conventional CD4+ T cells. Their stronger lineage commitment makes tTreg cells the safest cells to use in adoptive cell therapy, increasingly used to treat autoimmune and inflammatory disorders. Markers to distinguish human tTreg cells from pTreg cells have, however, not been found. Based on combined proteomic and transcriptomic approaches, we report that the Ig superfamily protein GPA33 is expressed on a subset of human Treg cells. GPA33 is acquired late during tTreg cell development but is not expressed on TGF-β-induced Treg cells. GPA33 identifies Treg cells in human blood that lack the ability to produce effector cytokines (IL-2, IFN-γ, IL-17), regardless of differentiation stage. GPA33high Treg cells universally express the transcription factor Helios that preferentially marks tTreg cells and can robustly and stably be expanded in vitro even without rapamycin. Expanded GPA33high Treg cells are suppressive, unable to produce proinflammatory cytokines, and exhibit the epigenetic modifications of the FOXP3 gene enhancer CNS2, necessary for indelible expression of this critical transcription factor. Our findings thus suggest that GPA33 identifies human tTreg cells and provide a strategy to isolate such cells for safer and more efficacious adoptive cell therapy.-
dc.language.isoeng-
dc.titleGPA33: A Marker to Identify Stable Human Regulatory T Cells.-
dc.typeJournal Article-
dc.identifier.journaltitleJournal of immunology (Baltimore, Md. : 1950)-
dc.identifier.affiliationDepartment of Hematopoiesis, Sanquin Research and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, 1066 CX Amsterdam, the Netherlands-
dc.identifier.affiliationDivision of Tumor Biology and Immunology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, the Netherlands-
dc.identifier.affiliationTumor Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationLa Trobe School of Cancer Medicine, La Trobe University, Melbourne, Victoria, VIC 3086 Australiaen
dc.identifier.affiliationDepartment of Hematopoiesis, Sanquin Research and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, 1066 CX Amsterdam, the Netherlands-
dc.identifier.affiliationDepartment of Molecular and Cellular Homeostasis, Sanquin Research and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, 1066 CX Amsterdam, the Netherlands-
dc.identifier.affiliationDepartment of Medical Immunology, Medical University of Gdańsk, 80-210 Gdańsk, Poland-
dc.identifier.affiliationDepartment of Experimental Immunology, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, the Netherlands-
dc.identifier.affiliationDepartment of Medical Immunology, Medical University of Gdańsk, 80-210 Gdańsk, Poland-
dc.identifier.affiliationDivision of Tumor Biology and Immunology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, the Netherlands-
dc.identifier.affiliationDepartment of Hematopoiesis, Sanquin Research and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, 1066 CX Amsterdam, the Netherlands-
dc.identifier.affiliationDepartment of Hematopoiesis, Sanquin Research and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, 1066 CX Amsterdam, the Netherlands;.-
dc.identifier.doi10.4049/jimmunol.1901250-
dc.identifier.orcid0000-0003-0148-7802-
dc.identifier.orcid0000-0001-9376-3231-
dc.identifier.orcid0000-0001-5287-5210-
dc.identifier.orcid0000-0002-6656-295X-
dc.identifier.pubmedid32366581-
dc.type.austinJournal Article-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

6
checked on Jan 22, 2021

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.